Stockscreener 앱 받기
0.00
100.00%
-4.66
전일 마감가:
$4.66
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.05B
수익:
$81.04M
순이익/손실:
$161.96M
주가수익비율:
0.00
EPS:
0.7146
순현금흐름:
$-144.00M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$5.72
큐어백 Stock (CVAC) Company Profile
Compare CVAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
0.00 | 1.05B | 81.04M | 161.96M | -144.00M | 0.7146 |
VRTX
Vertex Pharmaceuticals Inc
|
437.75 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.71 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.91 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.24 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
Health News Roundup: CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology; AstraZeneca's China boss says drugmaker will seek to "love the Communist Party" and more - Devdiscourse
CureVac NV stock (NL0015436031): merger integration and mRNA update - AD HOC NEWS
CureVac NV stock (NL0015436031): mRNA pioneer restructures and eyes next vaccine chapter - AD HOC NEWS
CureVac stock (NL0015436031): FDA clears deal path with GSK after BioNTech settlement - AD HOC NEWS
CureVac N.V.Ordinary Shares (NQ: CVAC - FinancialContent
TradingKey - TradingKey
CureVac NV stock (NL0015436031): Delisting amid liquidation process - AD HOC NEWS
5CV.DE Stock Bounces 0.72% on May 12 as CureVac Finds Support - Meyka
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Yahoo Finance
CureVac NV stock (NL0015436031): Is its mRNA platform strong enough to unlock new upside? - AD HOC NEWS
Risk Hedge: Should I hold or sell CureVac NV now2026 Winners & Losers & High Accuracy Investment Signals - baoquankhu1.vn
Signal Recap: Is CureVac NV likely to announce a buybackGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
Profit Recap: Should you avoid CureVac NV stock right now2026 Sentiment & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Aug Ideas: What is the Moat Score of CureVac NV2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Intraday Q1 preview 09 Apr 2026: 5CV.DE stock CureVac N.V. (XETRA): Key catalysts - Meyka
BNTX SEC FilingsBIONTECH 10-K, 10-Q, 8-K Forms - Stock Titan
Audit date correction in BioNTech (NASDAQ: BNTX) 20-F/A filing - Stock Titan
CureVac NV Stock: Biotech Innovator Focused on mRNA Technology and Oncology Pipeline for Long-Term I - AD HOC NEWS
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
Market Wrap: Is CureVac NV likely to announce a buybackWatch List & Capital Efficiency Focused Strategies - baoquankhu1.vn
Magnetar Financial LLC Takes $3.53 Million Position in CureVac N.V. $CVAC - MarketBeat
Earnings Miss: Is CureVac NV stock a buy or sellMarket Growth Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
CureVac (CVAC) Acquisition by BioNTech (BNTX): Your Portfolio Update - Gotrade
CVAC SEC FilingsCurevac B.V. 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
CureVac N.V. (CVAC) Investor Outlook: Analyzing the Biotech’s Future Amid Major Acquisition - DirectorsTalk Interviews
Aug Action: What is CureVac NVs TAM Total Addressable MarketJuly 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
BioNTech sets March 10 webcast for 2025 results update - Stock Titan
CEO Moves: Is CureVac N.V. stock a good dividend stockTreasury Yields & Daily Entry Point Trade Alerts - mfd.ru
CureVac N.V. (CVAC) Stock Analysis: Navigating A Transformational Path In Biotechnology - DirectorsTalk Interviews
CureVac (CVAC) Valuation Check After Phase 1 Brain Cancer Vaccine Milestone - Sahm
CureVac’s CVGBM Brain Cancer Vaccine Trial Reaches Completion: What It Means for CVAC Investors - TipRanks
Should you avoid CureVac N.V. stock right nowMarket Movement Recap & Fast Gaining Stock Reports - mfd.ru
New York Life Investment Management LLC Acquires Shares of 258,116 CureVac N.V. $CVAC - MarketBeat
Is CureVac N.V. stock trading near support levelsPortfolio Update Report & Community Driven Trade Alerts - mfd.ru
Is CureVac N.V. stock resilient to inflationMarket Sentiment Report & Technical Entry and Exit Alerts - mfd.ru
Alpine Associates Management Inc. Grows Stock Holdings in CureVac N.V. $CVAC - MarketBeat
CureVac’s Market Exit: A Chapter Closes in the mRNA Race - AD HOC NEWS
CureVac's Public Trading Era Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Delisted Following BioNTech Acquisition Completion () - aktiencheck.de
CureVac’s Market Exit: A New Chapter Begins Under BioNTech - AD HOC NEWS
CureVac's Public Market Journey Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Shares Cease Trading Following BioNTech Acquisition Finalization - AD HOC NEWS
CureVac Aktie: Vorhersehbare Kursbewegungen - Börse Global
CureVac Aktie: Glänzende Zukunftsperspektiven! - Börse Global
CureVac Concludes Nasdaq Listing Following BioNTech Acquisition - AD HOC NEWS
CureVac Shares Cease Trading Following BioNTech Acquisition - AD HOC NEWS
CureVac Aktie: Strategische Prioritäten - Börse Global
Block Trades: How does SIFY score in quality rankingsInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
CureVac N.V. (CVAC): Investor Outlook on the German mRNA Innovator Amidst Acquisition by BioNTech - DirectorsTalk Interviews
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
1.91%
자본화:
|
볼륨(24시간):